Trodelvy: All about the drug



Indication and Usage

The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC).

  • It is used when it is not possible to remove cancer with surgery.
  • Trodelvy comes in the form of single-dose vials in 180 mg for intravenous infusion.

Dosage

  • Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle.

Administration

  • First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction.
  • Subsequent Infusion: If the drug is tolerated in the first infusion, then a subsequent infusion of 1-2 hours has to be done, and after 30 minutes and during infusion, the patient should be observed for any reaction.

Premedication: 

Before infusion, antipyretic drugs are given in order to induce nausea and vomiting, as they are common side effects.

Contradictions and Precautions

  • TRODELVY (sacituzumab govitecan) should not be substituted with other drugs containing irinotecan or its active metabolite SN-38.
  • Adverse drug reactions can encompass hypersensitivity reactions, including severe anaphylactic reactions. In life-threatening cases, TRODELVY is discontinued.
  • TRODELVY can cause embryo-fetal toxicity as it crosses the placental barrier, and it is also advised not to breastfeed.
  • People who are homozygous for the UGT1A allele are at much higher risk for neutropenia, febrile neutropenia, and anemia.

Adverse drug reactions

  • Fatigue and loss of appetite are common side effects.
  • Decreased lymphocyte and leukocyte count.
  • Decreased hemoglobin and anemia.
  • Increased glucose and alkaline phosphate salts.

Packaging and Storing

  • Trodelvy for injection is a sterile, off-white to yellowish lyophilized powder in a single-dose vial.
  • Each vial of Trodelvy is individually boxed in a carton, and each vial has 180 mg of the drug.
  • It is stored in dark and cool places.

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more